generations of glp 1 agonists The Landscape GLP-1 Receptor In Diabetes And Obesity Treatment GLP-1 Receptor Agonist Market Growth

Furthermore, cardiovascular results for oral semaglutide were similar to the results observed in the SUSTAIN-6 trial with injectable semaglutide, suggesting that the oral and SC formulations share similar cardiovascular safety profiles

Andersen, B

While this study was not a head-to-head clinical trial comparison, it may be relevant that at week 12 of a weekly dosing regimen, some studies suggest that participants treated with semaglutide (Wegovy, Novo Nordisk) had an approximately 6% decrease from baseline in body weight, whereas those treated with tirzepatide (Zepbound, Eli Lilly) had an approximately 8% decrease from baseline in body weight at the same time period, Bays said

& Reid, D

doi: 10.1053/j.gastro.2007.03.054 [DOI] [PubMed] [Google Scholar] 24

Cancer Discov